In South Korea, A Growing Number Of COVID-19 Patients Test Positive After Recovery : Coronavirus Live Updates : NPR npr.org/sections/coron…

Brilliant 😄

Our open-access review on the structure and biophysics of Myc is out! Congratulations to the team Francisco Castillo and ⁦Laura Soucek⁩ #Peptomyc and #VHIO res.mdpi.com/d_attachment/c…

🔴 ÚLTIMA HORA | Barcelona ampliará aceras y carriles bici para minimizar los contagios. Lo acaba de anunciar la alcaldesa @adacolau . Sigue aquí los detalles del plan elperiodi.co/zlfmr1

#JobOffer: Peptomyc is hiring a Clinical Research Project Manager to work in #Barcelona ow.ly/DV4T30qjrwY #LifeSciences #oncology

Dermatologists around the world are gathering data on what may be largely overlooked symptoms of COVID-19: skin conditions ranging from rashes to “pseudo-frostbite” ti.me/3d2xiIQ

All of Prof. Feynman‘s lectures are now accessible online, for free. io9.gizmodo.com/you-can-now-ac…

A qué no os estabais colocando bien la mascarilla? 🤦🏻

The VHIO spin-off company #Peptomyc is developing a drug that inhibits the oncoprotein Myc. VHIO's Laura Soucek, Marie-Eve Beaulieu, Daniel Massó-Vallés and Francisco Castillo explore its development three recent publications. Read more via VHIO news👉vhio.net/en/researchers… #ICREA

Some good news for the planet! linkedin.com/posts/forbes-m…

Who are the Uighur people and why do they face oppression by China? independent.co.uk/news/world/asi…

The Chinese government is forcing Uighur Muslim women to insert IUDs and be sterilized in an effort to control the Uighur population.

Peptomyc is now a clinical stage company! I’m very proud and happy to have reached this great milestone! Congratulations for this excellent work, team. peptomyc.com/peptomyc-steps…

VHIO-born spin-off PEPTOMYC, co-founded in 2014 by VHIO’s Laura Soucek and Marie-Eve Beaulieu, announces the initiation of the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor, Omomyc. ➕ bit.ly/OmomycVHIOEng

#Peptomyc Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial. bit.ly/3h4mBKY

🔬 🏥 Arranca el ensayo clínico de Omomyc con la administración del fármaco 💊 al primer paciente en el Hospital Universitario Vall d’Hebron. ➕ bit.ly/EClinicoOmomyc…

Proud to participate to this beautiful initiative from #aseicamujer #CONOCELAS2022 and to present to teenagers the road that took me to live science every day! Orgullosa de participar y presentar hoy a adolescentes el camino que me ha llevado a vivir la ciencia cada día!

Peptomyc is pleased to announce that data of the phase 1 study with our lead compound OMO-103 (a first-in-modality pan-MYC inhibitor) will be presented for the first time by Dr.@ElenaGarralda at the 24th Symposium ENA 2022 taking place the next 26th-28th of October in Barcelona.

"City Science: Performance Follows Form" book presentation at the Smart City Expo World Congress, hosted by IESE Business School Prof. JE Ricart and Bàrbara Pons, with a distinguished panel: Hélène Chartier (C40), Laura Narváez (Foster & Partners), Ger Baron (Amsterdam). apply.iese.edu/smartcitysidee…

Peptomyc is awarded €5 million from the Horizon Europe #eicAccelerator to conduct a Phase 1b clinical trial with OMO-103 in first line metastatic pancreatic adenocarcinoma patients. Thanks to the European Innovation Council for their support! rb.gy/yyfwj